Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Stem Cell Culture01:17

Stem Cell Culture

Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

The New England journal of medicine·2026
Same author

Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis.

Blood advances·2026
Same author

Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer.

Nature biomedical engineering·2026
Same author

CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.

Nature medicine·2026
Same author

Factors Related to Long-Term Caregiving Burden Among Chimeric Antigen Receptor (CAR) T-Cell Recipients and Their Informal Caregivers.

Seminars in oncology nursing·2025
Same author

Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study.

Transplantation·2025

Related Experiment Video

Updated: May 12, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Cellular therapy following allogeneic stem-cell transplantation.

Alison Rager, David L Porter

    Therapeutic Advances in Hematology
    |April 5, 2013
    PubMed
    Summary

    Relapse after allogeneic stem cell transplant is common, but donor lymphocyte infusions can induce a graft-versus-leukemia effect. Minimizing graft-versus-host disease while enhancing graft-versus-leukemia response is key for improving outcomes.

    Keywords:
    allogeneicdonor leukocyte infusiongraft-versus-leukemia effecthematopoietic stem-cell transplantationrelapse

    More Related Videos

    Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
    08:52

    Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

    Published on: May 27, 2011

    Related Experiment Videos

    Last Updated: May 12, 2026

    Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
    11:55

    Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

    Published on: March 14, 2011

    Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
    08:52

    Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

    Published on: May 27, 2011

    Area of Science:

    • Hematology
    • Immunology
    • Oncology

    Background:

    • Allogeneic hematopoietic stem-cell transplantation (HSCT) is a primary treatment for hematologic malignancies.
    • Relapse post-HSCT is the leading cause of mortality, with poor prognosis for relapsed disease.
    • Graft-versus-leukemia (GVL) effects are crucial for long-term remission.

    Purpose of the Study:

    • To evaluate the efficacy of donor lymphocyte infusion (DLI) in inducing GVL effects post-HSCT.
    • To identify factors influencing DLI response in various hematologic malignancies.
    • To explore strategies for mitigating graft-versus-host disease (GVHD) while preserving GVL.

    Main Methods:

    • Review of DLI efficacy in patients with hematologic malignancies post-HSCT.
    • Analysis of factors affecting DLI response, including disease histology and relapse kinetics.
    • Assessment of GVHD incidence and its impact on immunotherapy outcomes.

    Main Results:

    • DLI has shown significant success in inducing GVL for relapsed chronic myelogenous leukemia.
    • Response rates to DLI in other hematologic malignancies are variable and less common.
    • GVHD frequently complicates DLI therapy, limiting its therapeutic potential.

    Conclusions:

    • While DLI can induce a GVL effect, its success is limited by disease type and GVHD.
    • Further research is needed to develop methods that minimize GVHD and maximize GVL for improved post-HSCT relapse management.